5-HT(2A) receptor antagonists block MK-801-induced stereotypy and hyperlocomotion

European Journal of Pharmacology

Volumn 358, Issue 2, 1998, Pages 111-116

  Ninan, Ipe ^a   Kulkarni, Shrinivas K ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

5 HT(2A) receptor antagonist; Hyperlocomotion; MK 801; Stereotypy

Indexed keywords

DIZOCILPINE; KETANSERIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RITANSERIN; SEGANSERIN; SEROTONIN 2A ANTAGONIST; DIZOCILPINE MALEATE; HISTAMINE H2 RECEPTOR ANTAGONIST; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; INTRAPERITONEAL DRUG ADMINISTRATION; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEREOTYPY; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG ANTAGONISM; MOTOR DYSFUNCTION;

ANIMALS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; HISTAMINE H2 ANTAGONISTS; KETANSERIN; LOCOMOTION; MALE; MICE; MICE, INBRED BALB C; NEUROPROTECTIVE AGENTS; PIPERIDINES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; RITANSERIN; SEROTONIN ANTAGONISTS; STEREOTYPIC MOVEMENT DISORDER;

EID: 0031593921     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00591-3     Document Type: Article

References (40)

1. Annies R., Loscher W. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191-194.
2. 2A receptor gene. Lancet. 346:1995;281-282.
3. Arvanov A.L., Liang X., Grossman S.S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-D-aspartate-and non-N-methyl-D-aspartate receptor mediated neurotransmission in rat prefrontal cortical neurons in vitro. J. Pharmacol. Exp. Ther. 283:1997;226-234.
4. Balster, R.L., 1987. The behavioural pharmacology of phencyclidine. In: Meltzer, H.Y. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, NY, pp. 1581-1579.
5. 2 receptor blocking agent. Curr. Ther. Res. Clin. Exp. 40:1986;492-499.
6. 2A receptor antagonist MDL 100907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse-implications for psychosis. J. Neural Transm. 100:1995;225-237.
7. Carlsson M., Carlsson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J. Neural Transm. 75:1989;221-226.
8. Carlsson M., Carlsson A. Dramatic synergism between MK-801 and clonidine with respect to locomotor stimulatory effect in monoamine-depleted mice. J. Neural Transm. 77:1989;65-71.
9. Carlsson M., Carlsson A. Interactions between glutamatergic and monoaminergic systems within basal ganglia-implications for schizophrenia and Parkinson's disease. Trends Neurosci. 13:1990;272-276.
10. 2 antagonist risperidone (R 64766) in the treatment of chronic psychosis: an open dose-finding study. Schizophr. Res. 2:1989;411-415.
11. Ceulemans D.L.S., Gelder Y.G., Hoppenbrouwers M.L.J.A., Reintjens A.J.M., Janssen P.A.J. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology. 85:1985;329-332.
12. Costall B., Naylor R.J. On the mode of action of apomorphine. Eur. J. Pharmacol. 21:1973;350-361.
13. Csernansky, J.G., Poscher, M., Faull, K.F., 1990. Serotonin in schizophrenia. In: Coccaro, E.F., Murphy, D.L. (Eds.), Serotonin in Major Psychiatric Disorders. American Psychiatric Press, Washington, DC, pp. 209-217.
14. Deutsch S.I., Mastropaolo J., Schwartz B.L., Rosse R., Morihisa J.M. A glutamatergic hypothesis of schizophrenia. Clin. Neuropharmacol. 12:1989;1-13.
15. 2 receptor antagonist, ritanserin, on biogenic amines in the rat nucleus accumbens. Eur. J. Pharmacol. 192:1991;429-437.
16. Gelders Y.G. Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiatry. 155:1989;33-36.
17. Grace A.A. Phasic vs. tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 41:1991;1-24.
18. Iverson, S.D., Singh, L., Oles, R.J., Preston, C., Tricklebank, M.D., 1988. Psychopharmacological profile of the N-methyl-D-aspartate (NMDA) receptor antagonist, MK-801. In: Domino, E.F., Kamenka, J.M. (Eds.), Sigma and Phencyclidine-like Compounds as Molecular Probes in Biology. NPP Books, Ann Arbor, MI, pp. 373-384.
19. Johnson Jr., K.M., 1987. Neurochemistry and neurophysiology of phencyclidine. In: Meltzer, H.Y. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, NY, pp. 1581-1579.
20. Koek W., Woods J.H., Winger G.D. MK-801, proposed non-competitive antagonist of excitatory aminoacid neurotransmission, produces phencyclidine-like behavioural effects in pigeons, rats and rhesus monkeys. J. Pharmacol. Exp. Ther. 245:1988;969-974.
21. 1A receptors. J. Pharmacol. Exp. Ther. 257:1991;1146-1153.
22. 1A receptor antagonist, (+)-WAY 100135, on stereotyped behaviour induced by the NMDA receptor antagonist dizocilpine in rats. Eur. J. Pharmacol. 242:1993;99-104.
23. Loscher W., Annies R., Honack D. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci. Lett. 128:1991;191-194.
24. Maj J., Rogoz Z., Skuza G. Locomotor hyperactivity induced by MK-801 in rats. Pol. J. Pharmacol. Pharm. 43:1991;449-458.
25. 2A receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transm. 104:1997;561-564.
26. Martin P., Waters N., Waters S., Carlsson A., Carlsson M.L. MK-801-induced hyperlocomotion: differential effects of M100907, SDZ PSD 958 and raclopride. Eur. J. Pharmacol. 335:1997;107-116.
27. Mathe J.M., Nomikos G.G., Hildebrand B.E., Hertel P., Svensson T.H. Prazocin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur. J. Pharmacol. 309:1996;1-11.
28. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology. 99:1989;S18-S27.
29. Nabeshima T., Yamaguchi K., Hiramatsu M., Amano M., Furukawa H., Kameyama T. Serotonergic involvement in phencyclidine-induced behaviours. Pharmacol. Biochem. Behav. 21:1984;401-407.
30. 2) receptor mediated enhancement of cortical unit activity. J. Physiol. Pharmacol. 70:1992;1604-1609.
31. Ninan I., Kulkarni S.K. Preferential blockade by clozapine of hyperlocomotion induced by non-competitive NMDA antagonist MK-801. Indian J. Physiol. Pharmacol. 42:1998;375-382.
32. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology. 110:1993;365-367.
33. Ping H.X., Xje L., Gong X.J., Liu G.Q., Wu H.Q. Effect of dizocilpine maleate on monoamines and their metabolites in rat brain. Acta Pharmacol. Sin. 13:1992;206-208.
34. Porter R.H., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 14:1994;7192-7199.
35. 2A receptor blockade. J. Pharmacol. Exp. Ther. 277:1996;1541-1549.
36. Sherman A.D., Hegwood T.S., Baruah S., Waziri R. Deficient NMDA-mediated glutamate release from synaptosomes of schizophrenics. Biol. Psychiatry. 30:1991;1191-1198.
37. 2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J. Pharmacol. Exp. Ther. 274:1995;735-740.
38. Van Kammen, D.P., Gelernter, J., 1987. Biochemical instability in schizophrenia: II. The serotonin and γ-aminobutyric acid systems. In: Meltzer, H.Y. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, NY, pp. 753-758.
39. Verma A., Kulkarni S.K. Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology. 107:1991;432-436.
40. Williams J., Spurlock G., McGuffin P., Mallet J., Nothen M.M., Gill M., Aschauer H., Hylander P., Macciardi F., Owen J.J. Association between schizophrenia and T 102C polymorphism of 5-hydroxytryptamine type 2a-receptor gene. Lancet. 347:1996;1294-1296.